Andy Rawstron
Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict <0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib+Venetoclax Arm of the FLAIR Trial
Rawstron, Andy; Webster, Nichola; Dalal, Surita; de Tute, Ruth M; Bell, Sue; Cairns, David Allan; Girvan, Sean; Greatorex, Natasha; Hockaday, Anna; Jackson, Sharon; Phillips, David; Stones, David; Allsup, David; Bloor, Adrian John Clifton; Sarma, Anita; Varghese, Abraham Mullasseril; Munir, Talha; Hillmen, Peter
Authors
Nichola Webster
Surita Dalal
Ruth M de Tute
Sue Bell
David Allan Cairns
Sean Girvan
Natasha Greatorex
Anna Hockaday
Sharon Jackson
David Phillips
David Stones
Professor David Allsup D.J.Allsup@hull.ac.uk
Professor of Haematology
Adrian John Clifton Bloor
Anita Sarma
Abraham Mullasseril Varghese
Talha Munir
Peter Hillmen
Citation
Rawstron, A., Webster, N., Dalal, S., de Tute, R. M., Bell, S., Cairns, D. A., Girvan, S., Greatorex, N., Hockaday, A., Jackson, S., Phillips, D., Stones, D., Allsup, D., Bloor, A. J. C., Sarma, A., Varghese, A. M., Munir, T., & Hillmen, P. Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict <0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib+Venetoclax Arm of the FLAIR Trial. Presented at 65th ASH Annual Meeting and Exposition, San Diego, CA
Presentation Conference Type | Conference Paper (published) |
---|---|
Conference Name | 65th ASH Annual Meeting and Exposition |
Acceptance Date | Oct 2, 2023 |
Online Publication Date | Nov 28, 2023 |
Publication Date | Nov 2, 2023 |
Deposit Date | Jan 17, 2024 |
Publicly Available Date | Nov 3, 2024 |
Journal | Blood |
Print ISSN | 0006-4971 |
Publisher | American Society of Hematology |
Peer Reviewed | Peer Reviewed |
Volume | 142 |
Issue | Supplement 1 |
Pages | 632-632 |
DOI | https://doi.org/10.1182/blood-2023-187943 |
Keywords | Cell Biology; Hematology; Immunology; Biochemistry |
Public URL | https://hull-repository.worktribe.com/output/4519285 |
Files
Accepted manuscript
(176 Kb)
PDF
Copyright Statement
Copyright 2023 by American Society of Hematology
You might also like
Epcoritamab in B-cell malignancies: current status and prospects
(2024)
Journal Article
Impact of Surface Ligand on the Biocompatibility of InP/ZnS Quantum Dots with Platelets
(2023)
Journal Article
Molecular Analysis at Relapse of Patients Treated on the Ibrutinib and Rituximab Arm of the National Multi-Centre Phase III FLAIR Study in Previously Untreated CLL Patients
(2023)
Presentation / Conference Contribution